浙江医学Issue(1)：29-32,4.
化疗前后CEA水平变化在晚期非小细胞肺癌患者疗效评价和预后判断中的价值
Serum CEA levels for evaluation of chemotherapy efficacy and prognosis in patients with advanced non-small cell lung cancer
赵同伟 1杨思福 1卢丽琴 1钦志泉 1袁国荣 1高亮 1陈永健 2孙馨 1陈韵 1洪朝金1
作者信息
- 1. 310014 杭州，浙江省人民医院肿瘤科
- 2. 310014 杭州，浙江省人民医院检验中心
- 折叠
摘要
Abstract
Objective To evaluate the chemotherapy efficacy and disease prognosis by using serum carcinoembryonic antigen (CEA) levels in patients with advanced non- smal celllung cancer (NSCLC). Methods The changes of serum CEA lev-els in 53 patients with NSCLC before and after 2 cycles of chemotherapy were retrospectively analyzed. Receiver operation char-acteristic (ROC) curve of CEA changes was used for evaluation of radiological disease control (DC). The correlation of CEA changes with progression- free survival (PFS) of patients were also analyzed. Results When the change rates of the CEA levels were used to evaluate DC of patients, the area of ROC curve was 0.794. Using cut- off value of- 34.0%CEA level changes, the sensitivity and specificity were 80.0% and 87.5%, respectively. Correlation regression analysis revealed that CEA change was positively correlated with DC (r=0.526, P<0.01). Univariate survival analysis showed that the PFS in patients with CEA reduction was longer than those without CEA reduction(6.87 vs 2.77 months, P<0.05). Multivariate survival analysis demonstrated that CEA change was an independent factor for PFS in NSCLC patients (P<0.05), as wel as chemotherapy cycles and weight loss (P<0.05). Conclusion The changes of CEA levels can effectively evaluate DC and predict PFS in advanced NSCLC patients with in-creased CEA levels.关键词
非小细胞肺癌/癌胚抗原/化疗/预测因子/预后Key words
Carcinoma non- smal- celllung cancer/Carcinoembryonic antigen/Drug therapy/Predictor factors/Prognosis引用本文复制引用
赵同伟,杨思福,卢丽琴,钦志泉,袁国荣,高亮,陈永健,孙馨,陈韵,洪朝金..化疗前后CEA水平变化在晚期非小细胞肺癌患者疗效评价和预后判断中的价值[J].浙江医学,2014,(1):29-32,4.
